

Please amend the subject application as follows:

In the Specification:

Please amend the specification at page 3, lines 17-31 through page 4, lines 1-4 as follows:

-- The invention provides a CTLA4Ig fusion protein reactive with B7 antigen and encoded by DNA deposited as ATCC 68629.

Further, the invention provides a CTLA4Ig fusion protein having the amino acid sequence of a CTLA4Ig fusion protein expressed by a cell deposited as ATCC 10762, wherein said CTLA4Ig fusion protein is reactive with B7 antigen.

The invention also provides a CTLA4Ig fusion protein expressed by a cell deposited as ATCC Accession No. 10762 and a CTLA4Ig fusion protein secreted by a cell deposited as ATCC Accession No. 10762.

Further, the invention provides a CTLA4Ig fusion protein having the amino acid sequence of a CTLA4Ig fusion protein secreted by a cell deposited as ATCC Accession No. 10762, wherein said CTLA4Ig fusion protein is reactive with B7 antigen.

~~The invention provides soluble CTLA4 mutant molecules that bind CD80 and/or CD86. In accordance with the practice of this invention, soluble CTLA4 molecules of the invention have amino acid changes in the extracellular domain of CTLA4 so as to produce molecules which would retain the functional property of CTLA4, namely, the mutant molecule will still bind either CD80, CD86, or both. In some embodiments, certain mutant molecules bind CD80 and/or CD86 with greater or similar avidity, compared to CTLA4.~~

~~CTLA4 mutant molecules comprise the extracellular domain of CTLA4 having an amino acid residue(s) replaced with another amino acid(s). The replacement amino acid residue can be any of the 20 natural amino acids or a non-naturally occurring amino acid. Embodiments of the mutant molecule include molecules having a single amino acid substitution at position S25, P26, G27, K28, A29, T30, E31, or R33. Other embodiments include mutant molecules having a single amino acid substitution at position K93, L96, M97, Y98, P99, P100, P101, Y102, or Y103. Additional embodiments includes mutant molecules having a single amino acid substitution at position L104, G105, I106, G107, Q111, Y113, or I115.~~

~~Examples of CTLA4 mutant molecules which bind CD86 more avidly than wildtype, e.g., CTLA4Ig, include certain mutants having amino acid substitutions at position S25, A29, T30, K93, L96, Y103, L104, or G105. --~~